{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:01:36Z","timestamp":1784718096945,"version":"3.55.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background\/objective<\/jats:title>\n                    <jats:p>Psychotropic medications are often associated with significant and rapid weight gain in pediatric populations, especially second-generation antipsychotics and mood stabilizers. This was a retrospective study assessing weight gain, and tolerability of adjunctive topiramate in hospitalized child and adolescent psychiatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 285 inpatients were included in the study: an intervention group (n = 45) receiving adjunctive topiramate and a control group (n = 240) receiving standard care. Net weight, polypharmacy burden (chlorpromazine [CPZ] equivalent doses and other mood stabilizers) and psychiatric recovery (Global Assessment of Functioning [GAF] and Clinical Global Impression-Severity [CGI-S] scores) were measured. Hierarchical ANCOVA models were employed to disentangle the independent metabolic effects of topiramate from the confounding effects of polypharmacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean weight gain in the control group was significantly greater than in the topiramate group (3.3\u00a0kg vs -0.1\u00a0kg, p &amp;lt; 0.001). This protective metabolic effect persisted with high statistical significance even after controlling for the concurrent CPZ equivalent dose (3.1\u00a0kg advantage). Clinical recovery, measured by equivalent improvement in GAF scores and reduction in CGI-S scores, was similar for both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adjunctive topiramate is a highly effective and safe metabolic shield in acute pediatric inpatient settings. It reduces the risk of psychotropic weight gain and can substantially reduce the need for obesogenic polypharmacy, without impeding the course of psychiatric recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1905527","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:10:20Z","timestamp":1784715020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Weight mitigation and tolerability of adjunctive topiramate in acute pediatric psychiatry: a retrospective real-world analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Binay","family":"Kayan Ocakoglu","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysegul","family":"Tonyali","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Bulanik Koc","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omca","family":"Guney","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seda","family":"Demirci","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131 Ece","family":"Soykut","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beyza","family":"Mentes","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukret","family":"Alev","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Karacetin","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Bak\u0131rk\u00f6y Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15543","article-title":"Efficacy of topiramate in reducing second-generation antipsychotic-associated weight gain among children: a systematic review and meta-analysis","volume":"26","author":"Costa","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1346-1","article-title":"The effects of antipsychotic medications on microbiome and weight gain in children and adolescents","volume":"17","author":"Bretler","year":"2019","journal-title":"BMC Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1637416","article-title":"Safety considerations in the psychopharmacology of pediatric bipolar disorder","volume":"18","author":"Sun","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/jrms.jrms_672_21","article-title":"Metabolic effects of adding topiramate on aripiprazole in bipolar patients aged between 6-18 years, a randomized, double-blind, placebo-controlled trial","volume":"27","author":"Arman","year":"2022","journal-title":"J Res Med Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.0037","article-title":"Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics","volume":"17","author":"Patel","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-013-0399-5","article-title":"Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review","volume":"22","author":"Mart\u00ednez-Ortega","year":"2013","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2004.06.006","article-title":"Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders","volume":"27","author":"Canitano","year":"2005","journal-title":"Brain Dev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1346-1","article-title":"A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders","volume":"14","author":"Hardan","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/chi.2022.0062","article-title":"Topiramate for weight management in children with severe obesity","volume":"19","author":"Berman","year":"2023","journal-title":"Childhood Obes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.931","article-title":"Adjunctive topiramate in hospitalized children and adolescents with bipolar disorders","volume":"15","author":"Barzman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1097\/01.PSYPHR.0000415488.63708.04","article-title":"Topiramate: off-label use in psychiatric disorders","volume-title":"Psychopharm Review","author":"Barnhorst","year":"2012"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12710","article-title":"Efficacy and safety of topiramate for reducing impulsivity: a transdiagnostic systematic review and meta-analysis of a common clinical use","volume":"36","author":"Chapron","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1369270","article-title":"Clinical effectiveness and predictors of response to topiramate plus lifestyle modification in youth with obesity seen in a weight management clinical setting","volume":"15","author":"Bomberg","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/0091217415621266","article-title":"Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: a medical record review","volume":"51","author":"Shapiro","year":"2016","journal-title":"Int J Psychiatry Med"},{"key":"B15","article-title":"Topiramate versus valproate sodium as adjunctive therapies to a combination of lithium and risperidone for adolescents with bipolar I disorder: effects on weight and serum lipid profiles","volume-title":"Iranian J Psychiatry","author":"Mahmoudi-Gharaei","year":"2012"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1905527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:10:23Z","timestamp":1784715023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1905527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":15,"alternative-id":["10.3389\/fpsyt.2026.1905527"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1905527","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1905527"}}